Health Care Giant McKesson Dives Amid Big Revenue Miss

McKesson (MCK), the drug and health supplies distribution giant, badly missed sales estimates for the June fiscal first quarter late Wednesday. Its earnings topped views, with the help of stock buybacks. MCK stock took a beating in early Thursday stock market action.

↑
X

NOW PLAYING
The Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave.

However, McKesson rivals Cencora (COR) and Cardinal Health (CAH) largely sidestepped any selling pressure. That suggests McKesson’s issues are specific to its business, rather than surfacing a wider problem for the health care sector.

McKesson cited a number of factors for the weaker-than-expected revenue, including a key customer’s “shift from brand to biosimilar” for Humira, used to treat arthritis. The company also cited “significant less demand” for Covid test kits and related products. Additionally, McKesson noted a slow pace of product launches in the quarter.

Analysts were somewhat mixed on the significance of the soft Q2 results. Baird cut its price target on the stock by 23 to 671, though keeping an outperform rating, after a second straight quarter of misses on most key performance indicators.

However, Barclays raised its price target by 20 to 616, saying it still thinks McKesson can grow EPS by at least 10% per year.

Despite the disappointing results, McKesson’s board approved a 15% dividend increase and authorized an additional $4 billion in stock buybacks.

McKesson Earnings

Estimates: Analysts expected EPS to dip 1% to $7.21, as revenue grew 11% to $82.53 billion.

Results: Adjusted EPS rose 8% to $7.88, though revenue rose 6% to $79.28 billion.

McKesson’s diluted share count fell 4% from a year ago, bolstering EPS. McKesson also cited pretax gains of $110 million from McKesson Ventures’ equity investments.

Outlook: McKesson raised its full-year EPS outlook to a range of $31.75 to $32.55, up 50 cents at the high and low end. Following the 67-cent EPS beat, the outlook for the second half of the year is a bit lighter than previously seen. Ahead of earnings, analysts were forecasting full-year EPS of $31.74.

MCK Stock Performance

McKesson shares dived 7% to 574 in early Thursday stock market action. McKesson has been a leader, hitting a record high last Friday, even as the broad market has come under pressure.

Cencora traded flat while Cardinal Health slipped 0.8%.

Be sure to read IBD’s The Big Picture column after each trading day to get the latest on the prevailing stock market trend and what it means for your trading decisions.

YOU MIGHT ALSO LIKE:

These Are The Best 5 Stocks To Buy And Watch Now

Join IBD Live Each Morning For Stock Tips Before The Open

IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today

How To Make Money In Stocks In 3 Simple Steps